<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black-translucent">

  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=0;"/>
  <!-- disable numbers becoming dialable -->
  <meta name="format-detection" content="telephone=no" />

  <link rel="stylesheet" href="css/slideshow.css" type="text/css" charset="utf-8">
  <link rel="stylesheet" href="css/thumbnailmenu.css" type="text/css" charset="utf-8">
  <link rel="stylesheet" href="css/topmenu.css" type="text/css" charset="utf-8">
  <link rel="stylesheet" href="css/referencepopup.css" type="text/css" charset="utf-8">
  
  <link rel="stylesheet" href="content/css/typography.css" type="text/css" charset="utf-8">
  <link rel="stylesheet" href="content/css/cover.css" type="text/css" charset="utf-8">
   
  <script type="text/javascript" src="viewer/js/monitor.js"></script>
  <script src="../viewer/js/pdf.js"></script>
  
  <script type="text/javascript" src="ALF/lib/zepto.js"></script>
  <script type="text/javascript" src="ALF/utils/dispatchEvent.js"></script>
  <script type="text/javascript" src="ALF/lib/touchy.js"></script>
  <script type="text/javascript" src="ALF/utils/utils.js"></script>
 
  <script type="text/javascript" src="ALF/controller/slidesnavcontroller.js"></script>
  <script type="text/javascript" src="ALF/controller/slidescroller.js"></script>
  <script type="text/javascript" src="ALF/model/model.js"></script>
  <script type="text/javascript" src="ALF/view/slides.js"></script>
  <script type="text/javascript" src="ALF/view/navigation.js"></script> 
  
  <script type="text/javascript" src="ALF/utils/drag.js"></script> 

  <script type="text/javascript" src="ALF/controller/menunavcontroller.js"></script>
  <script type="text/javascript" src="ALF/controller/thumbnavcontroller.js"></script>
  <script type="text/javascript" src="ALF/controller/footercontroller.js"></script>
  
  <script type="text/javascript" src="ALF/view/thumbnavigation.js"></script>
  <script type="text/javascript" src="ALF/view/footer.js"></script> 
 
  <script type="text/javascript" src="ALF/utils/include.js"></script>
  <script type="text/javascript" src="ALF/appinit.js"></script>
  
  <script type="text/javascript">
	 var path = 'content/slides/';
	 var jspath = 'content/js/';
	 var csspath = 'content/css/';
	 
	 var slidesarray = [['home'],
	                    ['pas', 'syringe', 'induction_dose', 'molecule'],
	                    ['week_52', 'week_0-6_7-12', 'week_12', 'week_1'],
	                    ['x-ray_data_withdrawers','x-ray_data_responders', 'probability', 'nice_criteria'],
	                    ['malignancies','infections', 'common_ae', 'history'],
	                    ['das28','haq-di'],
	                    ['injection_site_pain', 'productivity_home', 'productivity_work', 'sf-36', 'pain_and_fatigue'],
	                    ['nice', 'dosing', 'syringe'],
	                    ['end']];
	 
	 var topmenuarray = ['Start','Innovation','Rapid Response','Rapid Decision','Safety','Long Term Data','Quality of Life','Administration','Exit'];
	 
	 var utils = new Utils();
	 
	 for(var i = 0; i<slidesarray.length; i++) {
	     if(slidesarray[i].length > 1) {
	        for(var col = 0; col<slidesarray[i].length; col++){  
	             utils.includeCSS(slidesarray[i][col]);
	         }
	      } else if(slidesarray[i].length == 1){
	             utils.includeCSS(slidesarray[i]);
	      }
	 }	 
	 var model = new Model();
	 var app = new App();
	 var slideShow = new SlideShow();
	 
	 function init() {		  

		model.dynamic = true;
		app.init();
		slideShow.init = true;
		//new DragElement(document.getElementById('debugdiv'),'100','500');
		//monitoringEnabled = true;
	    document.addEventListener('swipeleft', function(){model.swipe = true});
	  } 
	 document.ontouchmove = function(e){
	     e.preventDefault();
	  }    	   
  	   window.addEventListener('load',init, false);
	</script>
  

<title>Cimzia</title>
  
</head>
<body>
<div id="debugdiv" class="debugdiv">Debug:</div>
<div id="container" class="container">
<div id="topnavwrapper">
</div> 
  
   <div id="wrapper">
    <div id="scroller">
   
       
	</div>
   </div>
   <!-- 
   <div id="cover" class="cover">
         <div id="cover" class="slide">  
         	 <div id="home_cover">
         	   <div class="slide_cover" id="home">
         	   <div class="frontLegCover"></div>
         	   <div class="frontSpafContainer">
         	   <div class="frontBrain"></div>
         	   <p class="frontTitle">Stroke Prevention<br />for Patients with Atrial Fibrillation</p>
         	   <div class="frontVein"><br /></div>
         	   </div>
         	   </div>
         	</div>
          </div>
   </div>
   
    <div id="thumbnav" class="thumbnav">
    	<div id="brain" class="branding"></div>
    </div> -->
   
    
   <div id="footer" class="footer"></div>  
   <div id="references_button" class="referencesbutton"></div>
</div>
   
   <div id="zoomWindow" class="zoomWindow">
   	  <div id="popupupContainer" class="popupContainer">
   	  <div id="popup" class="popup">
   	  <div class="text">
   	 <p>All values are expressed as event rate per 100 patient-years. Patients on Xarelto had significant<br /> increases in the following major bleeding events:.a ≥2 g/dL fall in haemoglobin (2.8% vs. 2.3%, P=0.019) and transfusions (1.7% vs. 1.3%, P=0.044).</p>
   	 <p><strong>Major bleeding</strong>: bleeding associated with a ≥2 g/dL fall in haemoglobin or requirement for transfusion of ≥2 units of packed red blood cells or .whole blood (clinically overt bleeding); the involvement of a critical site; or a fatal outcome.</p>
   	 <p><strong>Non-major clinically relevant bleeding</strong>: overt bleeding not meeting the criteria for major bleeding but associated with medical intervention; unscheduled contact with a physician; temporary study drug cessation; pain; or impairment of daily activities. ICH=intracranial haemmorhagic.</p>
   	  </div>
   	  </div>
   	  </div>
   </div>
   
   <div id="zoomWindow2" class="zoomWindow">
       <div id="popupupContainer" class="popupContainer">
       <div id="popup" class="popup">
       <div class="text">
   	   <p><strong><sup>a</sup>Major + Non-major clinically relevant bleeding:</strong> event rate per 100 patient-years (14.91 vs 14.52).<br />
   	  	 <strong><sup>b</sup>Major bleeding:</strong> bleeding associated with a ≥2 g/dL fall in haemoglobin or requirement for transfusion of ≥2 units of packed
   	  red blood cells or whole blood (clinically overt bleeding); the involvement of a critical site; or a fatal outcome. Event rate per 100
   	  patient-years (3.60 vs 3.45).<br />
   	  <strong><sup>c</sup>Non-major clinically relevant bleeding:</strong> overt bleeding not meeting the criteria for major bleeding but associated with
   	  medical intervention; unscheduled contact with a physician; temporary study drug cessation; pain; or impairment of daily activities.
   	  Event rate per 100 patient-years (11.80 vs 11.37).</p>
   	  </div>
   	 </div>
   	 </div>
   </div>
   
   <div id="popupWindow" class="popupWindow">
   	  <div id="popupupContainer" class="popupContainer">
   	  <div id="popup" class="popup">
   	        <h1>References</h1>
   			<ul slide-id="stroke_in_af" class="references">
   			 	<li>
   			 	<a href="javascript:openPDF('docs/Ref01_Di_Carlo-Humanandeconomicburdenofstroke.pdf');"><span>1.</span>
   			 	    Di Carlo A. Human and economic burden of stroke. Age Ageing. 2009;38(1):4-5. </a>
   			 	</li>
   			 	<li>
   			 	<a href="javascript:openPDF('docs/Ref02_Kannel-PrevalenceincidencePrognosis.pdf');"><span>2.</span>
   			 	  Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation:
   			 	  population-based estimates. Am J Cardiol. 1998;82(8A):2N-9N. </a>
   			 	</li>
   			 	<li>
   			 	<a href="javascript:openPDF('docs/Ref03_Marinietal-ContributionofAtrialFibrillationtoIncidenceandOutcomeofIschemicStroke.pdf');"><span>3.</span>
   			 	  Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke.
   			 	   2005;36(6):1115-1119.</a>
   			 	</li>
   			 	<li>
   			 	<a href="javascript:openPDF('docs/Ref04_Gladstone-PotentiallyPreventableStrokesinHigh-RiskPatientsWithAtrialFibrillation.pdf');"><span>4.</span>
   			 	   Gladstone DJ, Bui E, Fang J, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009;40(1):235-240. </a>
   			 	</li>
   			 </ul>
   			
   		 	<ul slide-id="current_treatment" class="references">
   		 		<li>
   		 		<a href="javascript:openPDF('docs/Ref04_Gladstone-PotentiallyPreventableStrokesinHigh-RiskPatientsWithAtrialFibrillation.pdf');"><span>4.</span>
   		 		   Gladstone DJ, Bui E, Fang J, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009;40(1):235-240. </a>
   		 		</li>
   		 		<li>
   		 		<a href="javascript:openPDF('docs/Ref05_Warfarin_SPC.pdf');"><span>5.</span>
   		 		    Warfarin [summary of product
   		 		    characteristics]. Frimley, Camberley, Surrey, United Kingdom: Sandoz Ltd; October 2010. </a>
   		 		</li>
   		 		<li>
   		 		<a href="javascript:openPDF('docs/Ref06_Waldo-HospitalizedPatientsWithAtrialFibrillationandaHighRiskofStroke.pdf');"><span>6.</span>
   		 		  Waldo AL, Becker RC, Tapson VF, et al; NABOR Steering Committee. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol. 2005;46(9):1729-1736. 
   		 		 </a>
   		 		</li>
   		 	</ul>
   		 	
   		 	<ul slide-id="xarelto_slide1" class="references">
   		 		<li>
   		 		<a href="javascript:openPDF('docs/7.pdf');"><span>7.</span>
   		 		   Xarelto [summary of product characteristics], draft. Leverkusen, Germany: Bayer HealthCare AG; December 2010.</a> 
   		 		</li>
   		 	</ul>
   		 	
   		 	<ul slide-id="xarelto_slide2" class="references">
   				<li>
   				<a href="javascript:openPDF('docs/7.pdf');"><span>7.</span>
   				   Xarelto [summary of product characteristics], draft. Leverkusen, Germany: Bayer HealthCare AG; December 2010.</a> 
   				</li>
   			</ul>
   		 	
   		 	<ul slide-id="efficacy_slide1" class="references">
   		 		<li class="none">
   		 		<span>12.</span>
   		 		  Data on file. Bayer HealthCare AG, Berlin, Germany.
   		 		</li>
   		 	</ul>
   		 	
   		 	<ul slide-id="efficacy_slide2" class="references">
   		 		<li class="none">
   		 		<span>12.</span>
   		 		  Data on file. Bayer HealthCare AG, Berlin, Germany.
   		 		</li>
   		 	</ul>
   		 	
   		 	<ul slide-id="rocketAF_slide1" class="references">
   			 	<li>
   			 	<a href="javascript:openPDF('docs/Ref11_DesignRocketAF.pdf');"><span>11.</span>
   			 	  The Executive Steering Committee, on
   			 	  behalf of the ROCKET AF Study Investigators. Rivaroxaban—once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of
   			 	  the ROCKET AF study. Am Heart J. 2010;159(3):340-347. </a>
   			 	</li>
   		 	</ul>
   		 	
   		 	<ul slide-id="rocketAF_slide2" class="references">
   		 		<li>
   		 		<a href="javascript:openPDF('docs/Ref11_DesignRocketAF.pdf');"><span>11.</span>
   		 		  The Executive Steering Committee, on
   		 		  behalf of the ROCKET AF Study Investigators. Rivaroxaban—once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of
   		 		  the ROCKET AF study. Am Heart J. 2010;159(3):340-347. </a>
   		 		</li>
   		 		<li class="none">
   		 		 <span>12.</span>
   		 		 Data on file. Bayer HealthCare AG, Berlin, Germany.
   		 		</li>
   		 	</ul>
   		 	
   		 	<ul slide-id="rocketAF_slide3" class="references">
   		 		<li>
   		 		<a href="javascript:openPDF('docs/Ref11_DesignRocketAF.pdf');"><span>11.</span>
   		 		  The Executive Steering Committee, on
   		 		  behalf of the ROCKET AF Study Investigators. Rivaroxaban—once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of
   		 		  the ROCKET AF study. Am Heart J. 2010;159(3):340-347. </a>
   		 		</li>
   		 		<li class="none">
   		 		 <span>12.</span>
   		 		 Data on file. Bayer HealthCare AG, Berlin, Germany.
   		 		</li>
   		 	</ul>
   		 	
   		 	<ul slide-id="rocketAF_slide4" class="references">
   		 		<li>
   		 		<a href="javascript:openPDF('docs/Ref13_Hacke-BaselinecharacteristicsofROCKETAFstudy.pdf');"><span>13.</span>
   		 		  Hacke W, Patel MR, Becker RC, et al. Baseline characteristics of the ROCKET AF study: comparison with recent
   		 		  atrial fibrillation studies. Abstract OAID 5 presented at the 19th European Stroke Conference (ESC); May 25-28, 2010: Barcelona, Spain 2010. 
   		 		  </a>
   		 		</li>
   		 	</ul>
   		 	
   		 	<ul slide-id="safety_slide1" class="references">
   		 		<li class="none">
   		 		 <span>12.</span>
   		 		  Data on file. Bayer HealthCare AG, Berlin, Germany.
   		 		</li>
   		 	</ul>
   		 	
   		 	<ul slide-id="safety_slide2" class="references">
   		 		<li class="none">
   		 		 <span>12.</span>
   		 		  Data on file. Bayer HealthCare AG, Berlin, Germany.
   		 		</li>
   		 	</ul>
   		 	
   		 	<ul slide-id="administration_slide" class="references">
   			 	<li>
   			 	<a href="javascript:openPDF('docs/7.pdf');"><span>7.</span>
   			 	   Xarelto [summary of product characteristics], draft. Leverkusen, Germany: Bayer HealthCare AG; December 2010.</a> 
   			 	</li>
   			 	<li>
   			 	<a href="javascript:openPDF('docs/Ref08_Perzborn-Thediscoveryanddevelopmentofrivaroxaban.pdf');"><span>8.</span>
   			 	  Perzborn E, Roehrig S, Straub A, et al. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov. 2010;10(1):61-75.</a>
   			 	</li>
   		 		<li class="none">
   		 		<span>12.</span>
   		 		Data on file. Bayer HealthCare AG, Berlin, Germany.
   		 		</li>
   		 		<li>
   		 		 <a href="javascript:openPDF('docs/Ref15_Kubitza-Safetypharmacodynamics.pdf');"><span>15.</span>
   		 		  Kubitza D, Becka M, Wensing G,
   		 		  et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct factor Xa inhibitor—after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61(12):873-880.</a>
   		 		</li>
   		 	</ul>
   		 	
   		 	<ul slide-id="summary_slide" class="references">
   			 	<li>
   			 	<a href="javascript:openPDF('docs/7.pdf');"><span>7.</span>
   			 	   Xarelto [summary of product characteristics], draft. Leverkusen, Germany: Bayer HealthCare AG; December 2010.</a> 
   			 	</li>
   			 	<li>
   			 	<a href="javascript:openPDF('docs/Ref09_Perzborn-Invitroandinvivostudiesofthenovelantithromboticagent.pdf');"><span>9.</span>
   			 	   Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic
   			 	   agent BAY 59-7939—an oral, direct factor Xa inhibitor. J Thromb Haemost. 2005;3(3):514-521. </a>
   			 	</li>
   		 		<li class="none">
   		 		<span>12.</span>
   		 		  Data on file. Bayer HealthCare AG, Berlin, Germany.
   		 		</li>
   		 	</ul>
   	  </div>
   	     <div class="closebutton" id="popupclosebutton"></div>
   </div>
   

    
  </div>
</body>
</html>   
